ATE538103T1 - Chinazolinonverbindungen als antikrebsmittel - Google Patents

Chinazolinonverbindungen als antikrebsmittel

Info

Publication number: ATE538103T1
Authority: AT; Austria
Prior art keywords: quinazolinone compounds; anticancer agents; quinazolinone; alone; compounds
Prior art date: 2003-11-25

Application number

AT04812051T

Other languages

English (en)

Inventor

Weibo Wang

Liana M Lagniton

Ryan N Constantine

Manoj C Desai

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-25

Filing date

2004-11-24

Publication date

2012-01-15

2004-11-24 Application filed by Novartis Ag filed Critical Novartis Ag

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538103T1 publication Critical patent/ATE538103T1/de

Links

AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title abstract 4
239000002246 antineoplastic agent Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04812051T 2003-11-25 2004-11-24 Chinazolinonverbindungen als antikrebsmittel ATE538103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52505903P	2003-11-25	2003-11-25
PCT/US2004/039448 WO2005051922A1 (en)	2003-11-25	2004-11-24	Quinazolinone compounds as anticancer agents

Publications (1)

Publication Number	Publication Date
ATE538103T1 true ATE538103T1 (de)	2012-01-15

Family

ID=34632957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04812051T ATE538103T1 (de)	2003-11-25	2004-11-24	Chinazolinonverbindungen als antikrebsmittel

Country Status (17)

Country	Link
US (2)	US7939539B2 (de)
EP (1)	EP1689724B1 (de)
JP (2)	JP4778439B2 (de)
KR (1)	KR20060127413A (de)
CN (1)	CN1886384A (de)
AT (1)	ATE538103T1 (de)
AU (1)	AU2004293464A1 (de)
CA (1)	CA2546932A1 (de)
CY (1)	CY1112478T1 (de)
DK (1)	DK1689724T3 (de)
ES (1)	ES2376552T3 (de)
IL (1)	IL175714A0 (de)
PL (1)	PL1689724T3 (de)
PT (1)	PT1689724E (de)
SG (1)	SG148202A1 (de)
SI (1)	SI1689724T1 (de)
WO (1)	WO2005051922A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6545004B1 (en) *	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US7671200B2 (en) *	1999-10-27	2010-03-02	Cytokinetics, Inc.	Quinazolinone KSP inhibitors
US7230000B1 (en) *	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
JP2005529076A (ja) *	2002-02-15	2005-09-29	サイトキネティクス・インコーポレーテッド	キナゾリノンの合成
EP1553931A4 (de) *	2002-05-09	2006-08-30	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
EP1513820A4 (de)	2002-05-23	2006-09-13	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
EP1537089A4 (de)	2002-07-23	2008-04-16	Cytokinetics Inc	Verbindungen, zusammenstellungen und verfahren
WO2004034972A2 (en) *	2002-09-30	2004-04-29	Cytokinetics, Inc.	Compounds, compositions, and methods
NZ551004A (en)	2004-04-02	2010-07-30	Prana Biotechnology Ltd	Neurologically-active compounds
EP1781674A1 (de)	2004-08-18	2007-05-09	AstraZeneca AB	Enantiomere von ausgewählten kondensierten pyrimidonen und anwendungen bei der behandlung und prävention von krebs
US20070207996A1 (en) *	2004-08-30	2007-09-06	Auger Kurt R	Novel Compositions And Methods Of Treatment
CA2584412C (en) *	2004-09-14	2017-05-09	Minerva Biotechnologies Corporation	Methods for diagnosis and treatment of cancer
CN101534824A (zh)	2006-11-17	2009-09-16	艾博特公司	作为化学活素受体拮抗剂的氨基吡咯烷
KR100916160B1 (ko) *	2007-02-21	2009-09-08	(주)바이오버드	약제학적 항암 조성물
WO2009102537A1 (en) *	2008-02-14	2009-08-20	Merck & Co., Inc.	Inhibitors of checkpoint kinases
CN101250189B (zh) *	2008-03-25	2010-06-16	中山大学	双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CN101857595B (zh) *	2010-05-21	2012-11-21	中山大学	一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009B (zh) *	2010-07-30	2012-04-04	江苏昊华精细化工有限公司	医药中间体4(h)喹唑酮的制造方法
CN101967127B (zh) *	2010-09-28	2013-05-29	中山大学	一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
DE102012101680A1 (de) *	2012-02-29	2013-08-29	Aicuris Gmbh & Co. Kg	Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2855483B1 (de)	2012-05-24	2017-10-25	Novartis AG	Pyrrolopyrrolidinonverbindungen
CN103012291B (zh) *	2012-12-17	2014-09-03	中山大学	一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用
AU2013364068B2 (en)	2012-12-21	2016-10-20	Gilead Calistoga Llc	Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja)	2012-12-21	2017-10-04	ギリアードカリストガエルエルシー	イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
WO2014115077A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Substituted purinone compounds
US9556180B2 (en)	2013-01-22	2017-01-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP3412675A1 (de)	2013-05-27	2018-12-12	Novartis AG	Imidazopyrrolidinonderivate und deren verwendung bei der behandlung einer krankheit
AU2014272700B2 (en)	2013-05-28	2016-12-01	Novartis Ag	Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2015016421A (es)	2013-05-28	2016-03-03	Novartis Ag	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PL3008053T3 (pl)	2013-06-14	2018-08-31	Gilead Calistoga Llc	Inhibitory 3-kinazy fosfatydyloinozytolu
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
EA029269B1 (ru)	2013-11-21	2018-02-28	Новартис Аг	Производные пирролопирролона и их применение для лечения заболеваний
RU2698697C2 (ru)	2013-12-23	2019-08-29	Байер Фарма Акциенгезельшафт	Конъюгаты связующего (ADC) с ингибиторами KSP
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2016020791A1 (en)	2014-08-05	2016-02-11	Novartis Ag	Ckit antibody drug conjugates
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2970565A1 (en)	2014-12-15	2016-06-23	Bayer Pharma Aktiengesellschaft	Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
JP6971858B2 (ja)	2015-06-22	2021-11-24	バイエルファーマアクチエンゲゼルシャフト	酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
EP3313521A1 (de)	2015-06-23	2018-05-02	Bayer Pharma Aktiengesellschaft	Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2016207104A1 (de)	2015-06-23	2016-12-29	Bayer Pharma Aktiengesellschaft	Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
US9957267B2 (en)	2015-07-01	2018-05-01	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3919518A1 (de)	2016-06-15	2021-12-08	Bayer Pharma Aktiengesellschaft	Spezifische antikörper-wirkstoff-konjugate mit ksp-inhibitoren und anti-cd123-antikörpern
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
CN110072556B (zh)	2016-12-21	2023-05-02	拜耳制药股份公司	具有ksp抑制剂的特异性抗体药物缀合物(adc)
CN110312534B (zh)	2016-12-21	2023-04-04	拜耳制药股份公司	具有酶促可裂解基团的抗体-药物-缀合物(adc)
EP3658560A4 (de)	2017-07-25	2021-01-06	Crinetics Pharmaceuticals, Inc.	Somatostatinmodulatoren und verwendungen davon
CN112601553A (zh)	2018-06-18	2021-04-02	拜耳股份有限公司	具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物
CN111499634B (zh) *	2019-01-31	2023-05-12	贝达药业股份有限公司	一种喹唑啉化合物及其在医药上的应用
WO2021086038A1 (ko)	2019-10-31	2021-05-06	홀로스메딕 주식회사	신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102682775B1 (ko)	2020-06-26	2024-07-08	홀로스메딕 주식회사	신규한 화합물의 제조방법
KR20220148758A (ko)	2021-04-29	2022-11-07	홀로스메딕 주식회사	신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102862736B1 (ko) *	2022-12-07	2025-09-22	부산대학교 산학협력단	신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4329418A1 (de) *	1993-09-01	1995-03-02	Agfa Gevaert Ag	Gelbkuppler
CZ20021428A3 (cs) *	1999-10-27	2002-11-13	Cytokinetics, Inc.	Způsoby a kompozice vyuľívající chinazoliny
US6545004B1 (en) *	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US6677110B2 (en) *	2001-03-30	2004-01-13	Fuji Photo Film Co., Ltd.	Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
JP4267838B2 (ja)	2001-03-30	2009-05-27	富士フイルム株式会社	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002296741A (ja)	2001-03-30	2002-10-09	Fuji Photo Film Co Ltd	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002318442A (ja)	2001-04-20	2002-10-31	Fuji Photo Film Co Ltd	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP4267840B2 (ja)	2001-04-20	2009-05-27	富士フイルム株式会社	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2005511581A (ja) *	2001-11-07	2005-04-28	メルク　エンド　カムパニー　インコーポレーテッド	有糸分裂キネシン阻害剤
CA2467722A1 (en) *	2001-12-06	2003-06-19	Merck & Co., Inc.	Thienopyrimidinone derivatives as mitotic kinesin inhibitors
EP1553931A4 (de)	2002-05-09	2006-08-30	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
EP1513820A4 (de)	2002-05-23	2006-09-13	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
EP1517904A4 (de)	2002-05-23	2007-02-21	Merck & Co Inc	Inhibitoren von mitotischem kinesin
WO2004018058A2 (en)	2002-08-21	2004-03-04	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2004034972A2 (en)	2002-09-30	2004-04-29	Cytokinetics, Inc.	Compounds, compositions, and methods

2004
- 2004-11-24 KR KR1020067012603A patent/KR20060127413A/ko not_active Withdrawn
- 2004-11-24 EP EP04812051A patent/EP1689724B1/de not_active Expired - Lifetime
- 2004-11-24 WO PCT/US2004/039448 patent/WO2005051922A1/en not_active Ceased
- 2004-11-24 SI SI200431833T patent/SI1689724T1/sl unknown
- 2004-11-24 CN CNA2004800348103A patent/CN1886384A/zh active Pending
- 2004-11-24 JP JP2006541684A patent/JP4778439B2/ja not_active Expired - Fee Related
- 2004-11-24 DK DK04812051.3T patent/DK1689724T3/da active
- 2004-11-24 ES ES04812051T patent/ES2376552T3/es not_active Expired - Lifetime
- 2004-11-24 SG SG200808730-6A patent/SG148202A1/en unknown
- 2004-11-24 AU AU2004293464A patent/AU2004293464A1/en not_active Abandoned
- 2004-11-24 AT AT04812051T patent/ATE538103T1/de active
- 2004-11-24 PT PT04812051T patent/PT1689724E/pt unknown
- 2004-11-24 CA CA002546932A patent/CA2546932A1/en not_active Abandoned
- 2004-11-24 PL PL04812051T patent/PL1689724T3/pl unknown
- 2004-11-24 US US10/996,814 patent/US7939539B2/en not_active Expired - Fee Related
2006
- 2006-05-17 IL IL175714A patent/IL175714A0/en unknown
2010
- 2010-12-21 JP JP2010285141A patent/JP2011084570A/ja not_active Withdrawn
2011
- 2011-04-12 US US13/085,048 patent/US20110190293A1/en not_active Abandoned
2012
- 2012-03-12 CY CY20121100255T patent/CY1112478T1/el unknown

Also Published As

Publication number	Publication date
CA2546932A1 (en)	2005-06-09
EP1689724A1 (de)	2006-08-16
PT1689724E (pt)	2012-02-06
KR20060127413A (ko)	2006-12-12
DK1689724T3 (da)	2012-02-27
JP4778439B2 (ja)	2011-09-21
US20110190293A1 (en)	2011-08-04
US20050209254A1 (en)	2005-09-22
EP1689724B1 (de)	2011-12-21
US7939539B2 (en)	2011-05-10
PL1689724T3 (pl)	2012-05-31
ES2376552T3 (es)	2012-03-14
SG148202A1 (en)	2008-12-31
WO2005051922A1 (en)	2005-06-09
JP2007512368A (ja)	2007-05-17
IL175714A0 (en)	2006-09-05
SI1689724T1 (sl)	2012-04-30
JP2011084570A (ja)	2011-04-28
CY1112478T1 (el)	2015-12-09
CN1886384A (zh)	2006-12-27
AU2004293464A1 (en)	2005-06-09

Publication	Publication Date	Title
ATE538103T1 (de)	2012-01-15	Chinazolinonverbindungen als antikrebsmittel
WO2005070930A3 (en)	2006-01-19	Tetrahydrocarboline compounds as anticancer agents
TW200505454A (en)	2005-02-16	Heteroaryl-fused pyrimidinyl compounds as anticancer agents
DE602004025698D1 (de)	2010-04-08	PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
WO2004006859A3 (en)	2004-07-01	Platinum compound
TW200718689A (en)	2007-05-16	2-Amino-quinazolin-5-ones
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
TW200716157A (en)	2007-05-01	Pharmaceutical formulations and methods of treatment using the same
IL176110A0 (en)	2006-10-05	Azabicyclic heterocycles as cannabinoid receptor modulators
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
TW200631578A (en)	2006-09-16	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
BRPI0414082A (pt)	2006-10-24	formas de dosagem de liberação sustentada de ziprasidona
TW200726765A (en)	2007-07-16	Triazolopyridine cannabinoid receptor 1 antagonists
MX2009003157A (es)	2009-04-03	Pirazoliltienopiridinas terapeuticas.
GT200900283A (es)	2011-10-05	"terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
TW200728304A (en)	2007-08-01	2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones
AR052774A1 (es)	2007-04-04	Inmunoterapia para trastornos autoinmunes
TW200722083A (en)	2007-06-16	Combinations and methods of using an indolinone compound
WO2005004808A3 (en)	2005-03-17	TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
WO2007062093A3 (en)	2008-10-23	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200716091A (en)	2007-05-01	New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2008008556A (es)	2008-09-26	Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
MX2021011289A (es)	2021-11-03	Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.